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After publication of this work [1], we noted that we in-
advertently failed to include the complete list of all coau-
thors and that sample sizes of some of the trials listed in
Table two were incorrect.
The full list of authors has now been added and includes
the names of all authors within the i-WIP Collaborative
Network. The Authors’ contributions and competing in-
terests section modified accordingly. We are publishing
this erratum to update the author list, which is as follows:
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Barakat Carballo, Maria Perales, Annick Bogaerts, Jose
G Cecatti, Fernanda Surita, Jodie Dodd, Julie Owens,* Correspondence: r.d.riley@bham.ac.uk
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Full list of author information is available at the end of the article
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Shub, Narges Motahari, Janette Khoury, Serena Tonstad,
Riitta Luoto, Tarja I Kinnunen, Kym Guelfi, Fabio Facchi-
netti, Elisabetta Petrella, Suzanne Phelan, Tânia T Scudeller,
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Mørkved, Kjell Åsmund Salvesen, Christina Vinter, Marcia
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Thangaratinam.
The sample sizes of trials included in Table two have
been corrected (Table 1). We are publishing this erratum to
update these trial sample sizes, which include Dodd 2014
(n = 2212), Prevedel 2003 (n = 41), Renault 2013 (n = 425),
Stafne 2012 (n = 855), Vinter 2011 (n = 360), Walsh 2012
(n = 800) and Wolff 2008 (n = 66).rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Studies with provisional support and consideration to share individual patient data
Study Year Country Study Characteristics Outcomes Sample size
Maternal Fetal
Althuizen 2012 Netherlands Ethnically diverse , no BMI restrictions, age n.r., GA at inclusion < 14 wks, glucose
status n.r., other risk factors: n.r.
GWG, GDM, preterm
delivery, CS
birth weight, macrosomia 269
Barakat 2009 Spain Caucasian, BMI restrictions n.r., age 25–35 yrs, GA at inclusion n.r. (total at least
26 wks intervention), glucose status n.r., no known pre-existing health problems
GWG, GA, preterm
delivery
birth weight, LGA, SGA, AS,
macrosomia (>4000g)
142
Barakat 2011 Spain Spanish (white), BMI restrictions n.r., age 23–38 yrs, GA at inclusion 1st prenatal
visit, glucose status n.r., no known pre-existing health problems
GWG, GA CS, vaginal
delivery
birth weight, AS 80
Barakat 2013 Spain Caucasian, no BMI restrictions, age n.r., GA at inclusion <10 wks, glucose status
n.r., no known pre-existing health problems
GWG, GA, GDM, PIH,
preterm delivery
birth weight, AS 765
Bogaerts 2012 Belgium Ethnically diverse , BMI≥ 29 kg/m2, age n.r., GA at inclusion < 15 wks,
nondiabetic, other risk factors: n.r
GWG, GA, PE, PIH, GDM,
IOL, CS, vaginal delivery
birth weight, AS 197
Cavalcante 2009 Brazil Race n.r., no morbid obesity, age restrictions n.r., GA at inclusion 16–20 wks,
glucose status n.r., no known pre-existing health problems
GWG, preterm delivery birth weight 71
Clapp 1997 USA Race n.r., no morbid obesity, age restrictions n.r., GA at inclusion 8 wks, glucose
status n.r., no known pre-existing health problems
GWG birth weight 51
Clapp 2000 USA Race n.r., no morbid obesity, age restrictions n.r., GA at inclusion 8 wks, glucose
status n.r., no known pre-existing health problems
GWG, GA birth weight 12
Dodd 2014 Australia Race n.r., BMI≥ 25 kg/m2, age restrictions n.r., GA at inclusion <20 wks,
nondiabetic, other risk factors: n.r.
PE, PIH, GDM, IOL, CS,
Preterm delivery
LGA, macrosomia (>4000g),
hypoglycaemia, shoulder dystocia,
admission to NICU
2,212
El Beltagy 2013 Egypt Race n.r., BMI: obese, age restrictions n.r., GA at inclusion: first antenatal visit, glucose
status n.r., other risk factors: n.r.
GWG, GDM birth weight, macrosomia 100
Grant 2013 Canada Race : predominantly non-Caucasian, BMI restrictions n.r., age >18 yrs, GA at inclusion
n.r., glucose status: impaired glucose tolerance or GDM, no known pre-existing health
problems
GWG birth weight, macrosomia 47
Guelinckx 2010 Belgium Caucasian, BMI≥ 29 kg/m2, age restrictions n.r., GA at inclusion <15 wks,
nondiabetic, no known pre-existing health problems
GWG, GA, PE, PIH, IOL,
CS
birth weight, LGA 85
Haakstad 2011 Norway Race n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion <24 wks,
glucose status n.r., no known pre-existing health problems
GWG 105
Hui 2006 Canada Ethnically diverse, BMI restrictions n.r., age restrictions n.r., GA at inclusion <26
wks, nondiabetic, no known pre-existing health problems
GWG, GA, GDM birth weight, LGA 45
Hui 2011 Canada Race n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion 20–26 wks,
nondiabetic, no known pre-existing health problems
GWG, GA, GDM, CS birth weight, LGA 224
Jackson 2010 USA Ethnically diverse, BMI restrictions n.r., age >18 yrs, GA at inclusion <26 wks,
glucose status n.r., other risk factors: n.r.
GWG 321
Jeffries 2009 Australia Race n.r., BMI restrictions none, age >18 - <45 yrs, GA at inclusion <14 wks,
nondiabetic, other risk factors: n.r.
GWG, PE, PIH, GDM ,
preterm delivery, CS
birth weight, LGA, SGA,
hypoglycaemia, shoulder dystocia
236
Khaledan 2010 Iran Race n.r., BMI restrictions n.r., age restrictions n.r., GA at inclusion 24–32 wks, no
Diabetes Mellitus type 1 (DM1) with poor control, no known pre-existing health
problems
GWG, GA, CS birth weight 39
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Table 1 Studies with provisional support and consideration to share individual patient data (Continued)
Khoury 2005 Norway Caucasian, BMI 19–32 kg/m2. age 21–38 yrs, GA at inclusion 17–20 wks,
nondiabetic, no known pre-existing health problems
GWG, PE, preterm
delivery
birth weight, SGA, intra-uterine death 290
Luoto 2011 Finland Race n.r., BMI >17 kg/m2, age >18 yrs, GA at inclusion 8–12 wks, nondiabetic, no
known pre-existing health problems
GWG, GA, PE, GDM birth weight, LGA, SGA 399
Nascimento 2011 Brazil Race n.r., BMI >26 kg/m2, age >18 yrs, GA at inclusion 14–24 wks, nondiabetic,
no known pre-existing health problems
GWG, PIH, GDM, CS birth weight, AS, LGA, SGA 82
Ong 2009 Australia Race n.r., obese, age restrictions n.r., GA at inclusion 18 wks, nondiabetic, other
risk factors: n.r.
GWG 12
Oostdam 2012 Netherlands Ethnically diverse, BMI≥ 25.0 kg/m2, age > 18 yrs, GA at inclusion <20 wks,
nondiabetic, no known pre-existing health problems
GWG, GDM birth weight 124
Petrella 2013 Italy Ethnically diverse , BMI≥ 25.0 kg/m2, age > 18 yrs, GA at inclusion 12 wks,
nondiabetic, no known pre-existing health problems
GWG, GDM, PIH, preterm
delivery
63
Phelan 2011 USA Ethnically diverse, BMI ≥19.8-26.0 kg/m2, age >18 yrs, GA at inclusion 10–16 wks,
glucose status n.r., no known pre-existing health problems
GWG, GA, PE, PIH, GDM,
preterm delivery, CS
birth weight, macrosomia, birth
weight <2500g
401
Poston 2013 United
Kingdom
Race: n.r., BMI ≥30 kg/m2, age restrictions n.r., GA at inclusion >15+0 weeks
and <17+6, , nondiabetic, no known pre-existing health problems
GA, GWG, PE, GDM,
mode of delivery
Birth weight, macrosomia, still birth 183
Prevedel 2003 Brazil Race: n.r., BMI restrictions n.r., age restrictions n.r. (primiparous or adolescents),
GA at inclusion 16–20 wks, glucose status n.a., no known pre-existing health
problems
GWG, preterm delivery birth weight, SGA 41
Rauh 2013 Germany Race: n.r., BMI ≥18.5 kg/m2, age ≥18 yrs, GA at inclusion <18 wks, nondiabetic, no
known pre-existing health problems
GWG, GDM, IOL, CS,
preterm delivery
Birth weight LGA, SGA 250
Renault 2013 Denmark Race: predominantly Caucasian, BMI ≥30 kg/m2, age >18 yrs, GA at inclusion <16
wks, nondiabetic, no known pre-existing health problems
GWG, GDM, PIH,PE,IOL,
CS, preterm delivery
Birth weight, SGA, LGA, Birth
weight >4000g
425
Sagedal 2014 Norway Race: n.r., BMI ≥19 kg/m2, age ≥18 yrs, GA at inclusion <20 wks, nondiabetic,
no known pre-existing health problems
GWG, GDM, CS LGA 606
Stafne 2012 Norway White, no BMI restrictions, age >18 yrs, GA at inclusion 18–22 wks, nondiabetic,
no known pre-existing health problems
GA, PE, PIH, GDM, CS birth weight, AS, LGA, admission to
NICU
855
Vesco 2013 USA Race: n.r., BMI ≥30 kg/m2, age n.r., GA at inclusion <20 wks, nondiabetic, no
known pre-existing health problems
GWG, GA, PE, PIH, GDM,
CS, preterm delivery
birth weight, LGA, SGA, macrosomia
(4000g)
114
Vinter 2011 Denmark Caucasian, BMI 30–45 kg/m2, age 18–40 yrs, GA at inclusion 10–14 wks,
nondiabetic, no known pre-existing health problems
GWG, PE, PIH, GDM, CS LGA, admission to NICU 360
Vitolo 2011 Brasil Race: n.r., BMI restrictions: none, age <35yrs, GA at inclusion 10–29 wks,
nondiagetic, no known pre-existing health problems
GWG,PE, PIH, GDM,
preterm birth
birth weight 315
Walsh 2012 Ireland Race: n.r., BMI restrictions n.r., age >18 yrs, GA at inclusion < 18 wks, nondiabetic,
no known pre-existing health problems
GWG, GA, preterm
delivery, IOL, CS
birth weight, macrosomia 800
Wolff 2008 Denmark Caucasian, BMI ≥30 kg/m2, age >18 - <45 yrs, GA at inclusion <18 wks, nondia-
betic, no known pre-existing health problems
GWG PE, PIH, GDM , CS birth weight 66
Yeo 2012 USA Ethnically diverse, BMI >19.8 kg/m2, no age restrictions, GA at inclusion 18 wks,
nondiabetic, no known pre-existing health problems
GWG, PE, PIH birth weight 17
AS Apgar score, CS Caesarean section, GA Gestational Age, GDM Gestational diabetes mellitus, GWG Gestational weight gain, IOL Induction of labour, LGA Large for gestational age, NICU Neonatal Intensive Care Unit,
n.r. not reported, PE Pre eclampsia, PIH Pregnancy Induced hypertension, RDS Respiratory Distress Syndrome, SGA Small for gestational age
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